CENTERS FOR MEDICARE & MEDICAID SERVICES

Medicare officials said 254,000 beneficiaries may have had identifying information exposed in a ransomware attack that occurred in October.

Lower-than-expected spending on Part B is allowing the Medicare program to reduce next year's premiums for beneficiaries.

The health care industry is obsessed with consumer satisfaction. But national patient surveys still don't get at an important question: Are hospitals delivering culturally competent care?

By clarifying what evidence it needs before it will pay for medicines like Aduhelm, health officials paved the way for improved drug innovation.

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs.

Medicare said Thursday it's considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer's drug projected to drive up program costs. The agency “is looking at that, and is still going through the process,” spokeswoman Beth Lynk said of a potential reduction in premiums, as Medicare announced its final coverage decision for Aduhelm, a drug whose benefits have been widely questioned in the medical community. Officials said Medicare will keep coverage restrictions imposed earlier on the $28,000-a-year medication, paying for Aduhelm only when it's used in clinical trials approved by the Food and Drug Administration or the National Institutes of Health.

A requirement to get vaccinated against COVID-19 kicks in Thursday for millions of health care workers in about half the states.

We question the magnitude of Eli Lilly’s decline for a few reasons.

Biogen drug, the first in decades approved to treat the disease, has sparked concerns about its high cost and efficacy.

Biogen drug, the first in decades approved to treat the disease, has sparked concerns about its high cost and efficacy.

Medicare officials were instructed Monday to reassess the standard monthly amount due to a reduction in the cost of a drug that caused half the premium jump.

Before you purchase a Medigap policy, you should make sure you understand their limitations and how they are priced.

There's reason to believe that current vaccines are going to be "quite effective" in combating the effects of the omicron strain, says Andy Slavitt.

Officials at The University of Texas MD Anderson Cancer Center will require all employees to be fully vaccinated for COVID-19 at the start of the new year.

The standard premium for Part B, which covers outpatient care and durable equipment, will be $170.10 next year, up $21.60 from $148.50 this year.

The Centers for Medicare & Medicaid Services is proposing to kill a regulation the agency finalized earlier this year under the Trump administration that would have required Medicare to pay for any medical device deemed as a "breakthrough" by the FDA.Driving the news: After receiving public feedback, CMS determined the rule was "not in the best interest of Medicare beneficiaries because the rule may provide coverage without adequate evidence that the breakthrough device would be a reasonable and

CMS is reviewing proposed rule that gives seniors access to critical FDA-approved medical products under Medicare.

Tuesday is the last day to sign up for Obamacare in 36 states, while another 14 and Washington, D.C. have later dates. The federal health insurance program — accessible at healthcare.gov — has seen a crush of signups as the open enrollment deadline approaches, and coronavirus cases continue to surge. Mr. Trump campaigned on "repealing and replacing" Obamacare during the 2016 election, and kept on message, albeit unsuccessfully, throughout his presidency. That argument, however, has not exactly been met with a warm reception by the conservative majority on the Supreme Court. Becerra was a leading advocate for passage of the ACA as California's attorney general, and has defended the law in federal court, including before the Supreme Court.

As part of our Ask 2 series, the newsroom will answer your questions about all things Houston. Question: When the COVID-19 vaccine is released to the public, how much is going to cost and who is going to pay for it? Answer: Recent reports offer hope that the coronavirus vaccine will be widely available at no additional cost in the United States. Under the Trump Administration, the Centers for Medicare & Medicaid Services (CMS) is taking steps to ensure all Americans have access to the COVID-19 vaccine at no cost when it becomes available, its website states. “Under President Trump’s leadership, we have developed a comprehensive plan to support the swift and successful distribution of a safe and effective vaccine for COVID-19,” CMS Administrator Seema Verma said.

NEW YORK (Reuters) - The Trump administration on Thursday said it will test allowing state Medicaid programs to limit health benefits and prescription drug coverage for some patients in return for changing how federal government contributions to the states are made. Medicaid plans currently pay for most prescription drugs. The program is primarily targeted at the roughly one-fifth of Medicaid patients who received health coverage through the Affordable Care Acts (ACA) Medicaid expansion program since 2014, CMS Administrator Seema Verma said. This is an opportunity for states to have greater negotiating power with manufacturers, Verma said on a conference call with reporters. Evercore ISI analyst Michael Newshel said the program could be in violation of Federal law, which requires Medicaid funding to be open ended.

NEW YORK (Reuters) - The Trump administration on Thursday said it would launch a pilot program that would allow states to limit health benefits for their Medicaid patients and negotiate drug prices on their behalf using an approach similar to commercial health plans. The administrations Centers for Medicare & Medicaid Services said states would have to opt into the Healthy Adult Opportunity program. It said participating states would be able to launch a formulary of covered drugs, which would allow them to negotiate to give drugmakers priority in the state in exchange for lower prices.